HDL Dysfunction During the Acute Stage of Stroke

Stroke, Acute Clinical Trial

— RUSH  

Official title:

HDL Dysfunction During the Acute Stage of Stroke

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03245957
• Other study ID #: 2016/CHU/06
• Status: Recruiting
• Start date: October 20, 2017
• Est. completion date: March 2020

Study information

• Verified date: March 2019
• Source: Centre Hospitalier Universitaire de la Réunion
• Contact: Christine JUHEL, PHD
• Phone: +262262359949
• Email: christine.juhel[@]chu-reunion.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study investigates the effect of plasma myeloperoxidase (MPO) concentrations on HDL dysfunction during the acute stage of ischemic and haemorrhagic strokes.

Description:

MRI or CT scan are used to confirm the diagnosis of haemorrhagic, ischemic and mimick stroke.

Plasma anf HDL-MPO concentrations, as well as potent HDL dysfunction, are compared in the 3 cases.

The investigators hypothesis is that MPO concentrations and subsequent HDL dysfunction could be higher in ischemic strokes than in haemorrhagic ones. MPO could be a examined as a potent marker of early stage of ischemic stroke.

Plasma MPO levels could also be discriminant regarding the mimick strokes in patient exhibiting stroke clinical picture.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 112
• Est. completion date: March 2020
• Est. primary completion date: October 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patients with less than 12 hours stroke clinical signs:

• hemiparesis or hemiplegia

• unilateral sensitivity disorder

• language impairment

• balance disorder

• dizziness, bilateral or monocular vision totally or partially lost

Exclusion Criteria:

• Pregnancy

• head trauma since the last 3 months

• stroke since the last 3 months

• myocardial infarction since the last 3 months

• patient disagrees to be enrolled in the study

Related Conditions & MeSH terms

• Stroke
• Stroke, Acute

Intervention

Other:
• Ischemic stroke
Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
• Haemorrhagic stroke
Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan

Locations

Country	Name	City	State
Réunion	Chu Reunion Island	Saint-Pierre	Reunion Island

Sponsors (2)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de la Réunion	Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

Réunion, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	HDL dysfunction	Assessment of HDL function using inhibition test on cell culture	Through study completion, an average of 6 hours
Primary	Plasma MPO concentrations	Assessment of plasma MPO concentrations during acute stage of stroke	Through study completion, an average of 6 hours
Secondary	HDL-MPO concentrations	Assessment of HDL-MPO concentrations during acute stage of stroke	Through study completion, an average of 6 hours